Advice
in the absence of a submission from the holder of the marketing authorisation.
miglustat (Zavesca ®) is not recommended for use within NHSScotland for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice45KB (PDF)
Medicine details
- Medicine name:
- miglustat (Zavesca)
- SMC ID:
- 632/10
- Indication:
- For the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease
- Pharmaceutical company
- Actelion Pharmaceuticals UK Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 12 July 2010